Janssen reveals new Spravato data
Period to remission was shortened with esketamine nasal spray in both sub-groups within study
Read More
Tag: Spravato
Depressive therapy Spravato demonstrates superior efficacy
Research supports use of Spravato nasal spray in adults with major depressive disorder
Read More
EU approves expanded use of Janssen’s Spravato
Treatment authorised for rapid reduction of depressive symptoms in a psychiatric emergency
Read More
SMC accepts 14 new medicines for use by NHS Scotland
The decisions bring a raft of new treatment options for conditions including epilepsy, depression and cancer
Read More
Janssen disappointed with second NICE no for Spravato
NICE has concerns with the evidence submitted but Janssen insists the nasal spray is a cost-effective use of NHS resources
Read More
Janssen’s depression nasal spray Spravato bags new FDA approval
Drug approved to treat major depressive disorder with acute suicidal ideation or behaviour
Read More
Janssen submits Spravato expansion in EU
The J&J division seeks to expand the use to adults with major depressive disorder who have current suicidal ideation with intent.
Read More
New data highlights value of Janssen’s Spravato
The approval of the drug is a new way of treating adults with TRD that is unlike other treatment options in psychiatry.
Read More
FDA approves nasal spray for treatment-resistant depression
The FDA has approved Johnson & Johnson’s Spravato for treatment-resistant depression, offering patients the first new treatment option in several years.
Read More
Spravato gets FDA Advisory Committee approval
FDA advisory committees have jointly voted in favour of approving Janssen’s Spravato nasal spray CIII for adults living with treatment-resistant depression.
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
